(S)-2-benzamido-N⁴-(4-(benzyloxy)-3-((benzyloxy)methyl)butyl)-N¹-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)succinamide | 1564251-54-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-benzamido-N⁴-(4-(benzyloxy)-3-((benzyloxy)methyl)butyl)-N¹-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)succinamide
• 英文别名: (2S)-2-benzamido-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-N'-[4-phenylmethoxy-3-(phenylmethoxymethyl)butyl]butanediamide
• CAS: 1564251-54-2
• 化学式: C₄₅H₆₀BN₃O₇
• 分子量: 765.798
• InChiKey: VMNWBKJOXQEROK-GAKADHCDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.53
• 重原子数：
  56
• 可旋转键数：
  20
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  124
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  tert-butyl N-[(2S)-1-[[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]amino]-1,4-dioxo-4-[[4-phenylmethoxy-3-(phenylmethoxymethyl)butyl]amino]butan-2-yl]carbamate 在 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 (S)-2-benzamido-N⁴-(4-(benzyloxy)-3-((benzyloxy)methyl)butyl)-N¹-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)succinamide
  参考文献：
  名称：

  Structurally Novel Highly Potent Proteasome Inhibitors Created by the Structure-Based Hybridization of Nonpeptidic Belactosin Derivatives and Peptide Boronates

  摘要：

  We previously developed highly potent proteasome inhibitor 1 (IC50 = 5.7 nM) and its nonpeptide derivative 2 (IC50 = 29 nM) by systematic structure-activity relationship studies of the peptidic natural product belactosin A and subsequent rational topology-based scaffold hopping, respectively. Their cell growth inhibitory activities, however, were only moderate (IC50 = 1.8 μM (1) and >10 μM (2)). We therefore planned to replace the unstable β-lactone warhead with a more stable boronic acid warhead. Importantly, belactosin derivatives bind mainly to the proteasome binding site, which is different from that occupied by known peptide boronate proteasome inhibitors such as bortezomib, suggesting that their hybridization might lead to the development of novel potent inhibitors. Here we describe design, synthesis, and biological activities of the newly developed potent hybrid proteasome inhibitors. Interestingly, these hybrids, unlike bortezomib, were highly selective for proteasomes and have long residence times despite having the same boronic acid warhead.

  DOI：

  10.1021/jm500045x

文献信息

• Structurally Novel Highly Potent Proteasome Inhibitors Created by the Structure-Based Hybridization of Nonpeptidic Belactosin Derivatives and Peptide Boronates
  作者：Shuhei Kawamura、Yuka Unno、Akira Asai、Mitsuhiro Arisawa、Satoshi Shuto

  DOI：10.1021/jm500045x

  日期：2014.3.27

  We previously developed highly potent proteasome inhibitor 1 (IC50 = 5.7 nM) and its nonpeptide derivative 2 (IC50 = 29 nM) by systematic structure-activity relationship studies of the peptidic natural product belactosin A and subsequent rational topology-based scaffold hopping, respectively. Their cell growth inhibitory activities, however, were only moderate (IC50 = 1.8 μM (1) and >10 μM (2)). We therefore planned to replace the unstable β-lactone warhead with a more stable boronic acid warhead. Importantly, belactosin derivatives bind mainly to the proteasome binding site, which is different from that occupied by known peptide boronate proteasome inhibitors such as bortezomib, suggesting that their hybridization might lead to the development of novel potent inhibitors. Here we describe design, synthesis, and biological activities of the newly developed potent hybrid proteasome inhibitors. Interestingly, these hybrids, unlike bortezomib, were highly selective for proteasomes and have long residence times despite having the same boronic acid warhead.